News & Events
Published On: 5/7/2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
DURHAM, N.C., May 7, 2020 /PRNewswire/ -- TARGET PharmaSolutions, an innovative healthcare data company that generates real-world clinical data and evidence, announced today the latest research findings from its inflammatory bowel disease study (TARGET-IBD), which was published in the May issue of the peer-reviewed journal Gastroenterology.
The abstract, "Objective Disease Activity Assessment and Therapeutic Drug Monitoring (TDM) is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD," was accepted to the annual Digestive Disease Week conference, originally planned to take place in Chicago.
The research aimed to describe the objective marker and therapeutic drug monitoring assessments used in routine clinical practice, prior to biologic therapeutic changes due to loss of response in adult participants. More than 30% of both Crohn's disease and ulcerative colitis patients lacked any type of assessment in the 12 weeks leading up to dose changes; for dose discontinuations, this value was over 20%.
"This analysis brought to light that objective monitoring prior to changes in therapeutics is lacking in many cases," said first author Benjamin Click, MD, staff gastroenterologist at Cleveland Clinic. "Improved understanding of reasons for failure may optimize biologic positioning and outcomes in IBD."
TARGET-IBD is a prospective longitudinal cohort of over 4,000 IBD patients receiving usual care from 34 academic and community centers throughout the U.S. Data is collected retrospectively for three years from the patient's date of consent and then prospectively for at least five years. The resultant robust cohort allows for the collection of effectiveness and safety data upon new drug approvals.
An additional abstract was submitted by TARGET PharmaSolutions for its nonalcoholic steatohepatitis (NASH) study, TARGET-NASH, and was also accepted for publication. Gastroenterology is the official journal of the American Gastroenterological Association Institute.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
10/11/2021Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
09/13/2021Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting
07/01/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients